Ultrasensitive AMH testing maps ovarian reserve in midlife women

Between 35 and 55, a woman's body enters a territory that medicine has long treated as a single, undifferentiated zone. Her fertility declines. Hot flashes arrive without warning. The markers that once reliably signaled her reproductive status begin to flicker and fade. For decades, clinicians have relied on a hormone called anti-Müllerian hormone, or AMH, to measure what remains of a woman's egg supply—her ovarian reserve. But the tools available have been blunt. Most reference ranges were built from younger women. The tests themselves couldn't reliably detect the very low levels that characterize a woman in her mid-forties or approaching menopause. The result was a gap: doctors could see that something was changing, but not precisely what, or how it compared to her peers.

A research team led by Yingying Qin at Shandong University, working with Ruimin Zheng at China's National Center for Women and Children's Health, set out to close that gap. They built an age-specific reference table for Chinese women aged 35 to 55 using data from a large nationwide cohort and a new ultrasensitive AMH assay. The assay could measure AMH with precision in the range where it matters most—particularly between ages 44 and 49, when levels approach what researchers call a "near-depletion" phase. The result was what the team describes as a coordinate map: a clinician can now locate a woman's exact age on one axis, her AMH value on another, and see at a glance whether her ovarian reserve sits ahead of or behind that of her peers. The study appeared online in the Chinese Medical Journal on August 17, 2026.

The practical implications emerged when the team tested this framework in a hospital-based cohort of women aged 35 to 40 still planning to conceive. Those whose baseline AMH fell below the 10th percentile for their age faced a substantially higher risk of progressing to severely diminished ovarian reserve—defined as less than 0.25 nanograms per milliliter—compared to women in the normal range. For women attempting pregnancy in their late thirties or early forties, this kind of early warning carries weight. It offers something concrete to build fertility counseling around: not just "your reserve is low," but "your reserve is lower than 90 percent of women your age, and that carries these specific risks."

Beyond fertility, the research surfaced a connection that has received little clinical attention. Women with lower AMH levels reported more severe perimenopausal symptoms, particularly vasomotor symptoms like hot flashes and night sweats. This finding suggests that AMH could function as an objective marker to complement the symptom questionnaires clinicians typically use. Rather than relying solely on a woman's description of her symptoms, a doctor could reference her AMH level and consider whether hormone replacement therapy or other interventions might be warranted. The implication is subtle but significant: a biological measurement could help personalize care in a phase of life where symptoms are often minimized or attributed to stress.

The team also examined whether ultrasensitive AMH testing could help identify menopause itself. They found a sharp drop in AMH between premenopausal and postmenopausal women—0.187 nanograms per milliliter versus 0.043. Yet AMH alone proved only moderately useful as a diagnostic tool, with a discriminative performance around 0.7 on a scale where 1.0 is perfect. In other words, AMH cannot stand alone as a menopause test. But in situations where other hormones like FSH and estradiol fluctuate unpredictably—making diagnosis clinically murky—an extremely low AMH value can provide useful supporting evidence.

What the research ultimately offers is a more granular map of a transition that has long been treated as a blur. For women in their late reproductive years, it enables earlier identification of those at risk of rapid ovarian reserve decline, giving them time to make informed decisions about fertility. For women navigating the perimenopausal years, it provides a biological anchor for symptom management, moving care away from one-size-fits-all approaches. The age-specific reference ranges address a real clinical gap: most existing AMH standards were built from younger women, leaving doctors without precise guidance for the very population most in need of it. Whether this framework will be adopted beyond China, and whether it will shift how midlife women's health is managed globally, remains to be seen. But the research demonstrates that precision—the ability to measure what is actually happening in a woman's body at her specific age—can open doors that broader categories have kept closed.